#CCTG2023 Wednesday, April 12, 2023 The CCTG Plenary Session will be held at the Annual Spring Meeting of Participants on Friday April 28, 2023 from 4:30 – 5:30 pm in the Mountbatten room at the Chelsea Hotel in Toronto. The session will feature discussion on four outstanding clinical trials, CX1 (SHAPE) IND227 Phase II results, ENC1 a Phase III study, and the HE1 Phase III study. The co-chairs for the Plenary Session are: Ms. Judy Needham, Dr. Pierre-Olivier Gaudreau, Dr. Chris O’Callaghan, Dr. Wendy Parulekar Dr. Marie Plante 4:30 – 4:45 CX5: SHAPE – A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early-Stage Cervical Cancer Dr Plante is a Professor in Obstetrics and Gynecology at Laval University. She was Vice-President of the International Gynecologic Cancer Society and is currently past Chair of the Cervical Cancer Research Network. She is interested in minimally invasive surgery, sentinel node mapping and fertility-preserving surgery in cervical cancer. Dr. Quincy Chu 4:45 – 5:00 IND227: A Phase II/III Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma – Phase II Results Dr. Chu has extensive clinical research experience in novel therapeutics, thoracic malignancies and experimental therapeutics as well as preclinical and translational research collaboration in the development of new cancer therapeutics. He is Chair of the CCTG IND committee and member of the Lung Executive Committee. He is also co-lead of the Phase I program and Thoracic Oncology Group of the Cross Cancer Institute. Dr. Stephen Welch 5:00 – 5:15 ENC1: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Dr. Stephen Welch Associate Professor, Department of Oncology at Western University and Medical Oncologist, London Health Sciences Centre. He specializes in treatment of gastrointestinal and gynecologic malignancies. Dr Welch is the Co-Chair of the CCTG Gynecologic Cancer Disease Site Group and is the President-Elect for the Canadian Association of Medical Oncologists. Dr. Laura Dawson 5:15 – 5:30 HE1: Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases Laura Dawson is Professor and Chair of the Department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist at the Radiation Medicine Program, Princess Margaret Cancer Centre. She is an internationally recognized leader in hepatobiliary cancer and in oligo-metastases.
